Board meeting on Oct 21 to approve Q2 and H1 FY27 results

Revenue declinedEBITDA margin expansionNegative operating cash flowResults View source PDF Explain this filing

NURECA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹324.00

prior close

₹324.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%+0.1% vs market

Medical Equipment & Supplies peers, median of 12sector-1.0%-0.5% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 0.5 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-1.5

15m

+1.5

30m

+1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5-1.6+0.1-1.0-0.5

Next day

+0.3-1.0+1.2+0.0+0.3

-2.1-2.6+0.5-1.4-0.8

+1.5-5.1+6.7-4.9+6.4

+1.3-6.1+7.4-4.7+6.0

-2.3-8.3+6.0-7.5+5.3

-4.3-6.4+2.0-5.3+1.0

15d

-7.4pendingpending+0.3-7.7

—————

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 12Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Nureca Limited's Board of Directors will meet on Wednesday, October 21, 2026, to consider and approve the un-audited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2026. The intimation was filed with BSE and NSE on October 14, 2026, under SEBI LODR Regulations 29 and 30. No other agenda items were disclosed in the notice.

Likely market impact

Q2 and H1 FY27 results on Oct 21 may drive short-term stock moves. Investors should watch revenue, margins, and PAT versus prior periods.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹58.53 Cr	₹71.92 Cr	−18.6%
Operating profit	₹4.16 Cr	₹0.94 Cr	+344.8%
Profit after tax	₹4.05 Cr	₹4.44 Cr	−8.8%
EBITDA margin	8.9%	3.8%	+5.2 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.